Subcutaneous fast-acting insulin analogues, alone or in combination with long-acting insulin, versus intravenous regular insulin infusion in patients with diabetic ketoacidosis: protocol for an updated systematic review and meta-analysis of randomised trials

Introduction Diabetic ketoacidosis (DKA) is traditionally managed using intravenous regular insulin infusion (RII) in intensive care unit (ICU)/high dependency unit (HDU). Subcutaneous fast-acting insulin analogues (FAIAs) may help to manage DKA outside ICU/HDU. Furthermore, combining subcutaneous l...

Full description

Saved in:
Bibliographic Details
Main Authors: Beng Leong Lim, Wei Feng Lee, Berlin Lee, Yan Ee Lynette Chung, Kee Vooi Loo
Format: Article
Language:English
Published: BMJ Publishing Group 2023-02-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/13/2/e070131.full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850023659201101824
author Beng Leong Lim
Wei Feng Lee
Berlin Lee
Yan Ee Lynette Chung
Kee Vooi Loo
author_facet Beng Leong Lim
Wei Feng Lee
Berlin Lee
Yan Ee Lynette Chung
Kee Vooi Loo
author_sort Beng Leong Lim
collection DOAJ
description Introduction Diabetic ketoacidosis (DKA) is traditionally managed using intravenous regular insulin infusion (RII) in intensive care unit (ICU)/high dependency unit (HDU). Subcutaneous fast-acting insulin analogues (FAIAs) may help to manage DKA outside ICU/HDU. Furthermore, combining subcutaneous long-acting insulin (LAI) with subcutaneous FAIAs may accelerate ketoacidosis resolution. The latest (2016) Cochrane review was inconclusive regarding subcutaneous FAIAs versus intravenous RII in DKA. It was limited by small sample sizes, unclear risk of bias (RoB) in primary trials and did not examine subcutaneous FAIAs with subcutaneous LAI versus intravenous RII in DKA. We report the protocol for an updated meta-analysis on the safety and benefits of subcutaneous FAIAs with/without subcutaneous LAI versus intravenous RII in DKA.Methods and analysis We will search Medline, Embase, CINAHL and Cochrane Library, from inception until December 2022, without language restrictions, for randomised trials on subcutaneous FAIAs with/without subcutaneous LAI versus intravenous RII in DKA. We also search ClinicalTrials.gov, ClinicalTrialsRegister.eu and reference lists of included trials. Primary outcomes include all-cause in-hospital mortality, time to DKA resolution, in-hospital DKA recurrence and hospital readmission for DKA post-discharge. Secondary outcomes include resource utilisation and patient satisfaction. Safety outcomes include important complications of DKA and insulin. Reviewers will extract data, assess overall RoB and quality of evidence using Grading of Recommendations, Assessment, Development and Evaluation. We will assess statistical heterogeneity by visually inspecting forest plots and the I2 statistic. We will synthesise data using the random-effects model. Predefined subgroup analyses are: mild versus moderate versus severe DKA; age <20 vs ≥20 years; pregnant versus non-pregnant; infective versus non-infective DKA precipitating cause; subcutaneous FAIAs alone versus subcutaneous FAIAs and subcutaneous LAI; and high versus low overall RoB. We will also perform trial sequential analysis for primary outcomes.Ethics and dissemination Ethics board approval is not required. Results will be disseminated through publication in a peer-reviewed journal.PROSPERO registration number CRD42022369518.
format Article
id doaj-art-98bda250a0d3418c8c4ff843cc20b048
institution DOAJ
issn 2044-6055
language English
publishDate 2023-02-01
publisher BMJ Publishing Group
record_format Article
series BMJ Open
spelling doaj-art-98bda250a0d3418c8c4ff843cc20b0482025-08-20T03:01:19ZengBMJ Publishing GroupBMJ Open2044-60552023-02-0113210.1136/bmjopen-2022-070131Subcutaneous fast-acting insulin analogues, alone or in combination with long-acting insulin, versus intravenous regular insulin infusion in patients with diabetic ketoacidosis: protocol for an updated systematic review and meta-analysis of randomised trialsBeng Leong Lim0Wei Feng Lee1Berlin Lee2Yan Ee Lynette Chung3Kee Vooi Loo4Department of Emergency Medicine, Ng Teng Fong General Hospital, National University Health System, SingaporeDepartment of Emergency Medicine, Ng Teng Fong General Hospital, National University Health System, SingaporeEmergency Medicine, Ng Teng Fong General Hospital, SingaporeEmergency Medicine, Ng Teng Fong General Hospital, SingaporeEmergency Medicine, Ng Teng Fong General Hospital, SingaporeIntroduction Diabetic ketoacidosis (DKA) is traditionally managed using intravenous regular insulin infusion (RII) in intensive care unit (ICU)/high dependency unit (HDU). Subcutaneous fast-acting insulin analogues (FAIAs) may help to manage DKA outside ICU/HDU. Furthermore, combining subcutaneous long-acting insulin (LAI) with subcutaneous FAIAs may accelerate ketoacidosis resolution. The latest (2016) Cochrane review was inconclusive regarding subcutaneous FAIAs versus intravenous RII in DKA. It was limited by small sample sizes, unclear risk of bias (RoB) in primary trials and did not examine subcutaneous FAIAs with subcutaneous LAI versus intravenous RII in DKA. We report the protocol for an updated meta-analysis on the safety and benefits of subcutaneous FAIAs with/without subcutaneous LAI versus intravenous RII in DKA.Methods and analysis We will search Medline, Embase, CINAHL and Cochrane Library, from inception until December 2022, without language restrictions, for randomised trials on subcutaneous FAIAs with/without subcutaneous LAI versus intravenous RII in DKA. We also search ClinicalTrials.gov, ClinicalTrialsRegister.eu and reference lists of included trials. Primary outcomes include all-cause in-hospital mortality, time to DKA resolution, in-hospital DKA recurrence and hospital readmission for DKA post-discharge. Secondary outcomes include resource utilisation and patient satisfaction. Safety outcomes include important complications of DKA and insulin. Reviewers will extract data, assess overall RoB and quality of evidence using Grading of Recommendations, Assessment, Development and Evaluation. We will assess statistical heterogeneity by visually inspecting forest plots and the I2 statistic. We will synthesise data using the random-effects model. Predefined subgroup analyses are: mild versus moderate versus severe DKA; age <20 vs ≥20 years; pregnant versus non-pregnant; infective versus non-infective DKA precipitating cause; subcutaneous FAIAs alone versus subcutaneous FAIAs and subcutaneous LAI; and high versus low overall RoB. We will also perform trial sequential analysis for primary outcomes.Ethics and dissemination Ethics board approval is not required. Results will be disseminated through publication in a peer-reviewed journal.PROSPERO registration number CRD42022369518.https://bmjopen.bmj.com/content/13/2/e070131.full
spellingShingle Beng Leong Lim
Wei Feng Lee
Berlin Lee
Yan Ee Lynette Chung
Kee Vooi Loo
Subcutaneous fast-acting insulin analogues, alone or in combination with long-acting insulin, versus intravenous regular insulin infusion in patients with diabetic ketoacidosis: protocol for an updated systematic review and meta-analysis of randomised trials
BMJ Open
title Subcutaneous fast-acting insulin analogues, alone or in combination with long-acting insulin, versus intravenous regular insulin infusion in patients with diabetic ketoacidosis: protocol for an updated systematic review and meta-analysis of randomised trials
title_full Subcutaneous fast-acting insulin analogues, alone or in combination with long-acting insulin, versus intravenous regular insulin infusion in patients with diabetic ketoacidosis: protocol for an updated systematic review and meta-analysis of randomised trials
title_fullStr Subcutaneous fast-acting insulin analogues, alone or in combination with long-acting insulin, versus intravenous regular insulin infusion in patients with diabetic ketoacidosis: protocol for an updated systematic review and meta-analysis of randomised trials
title_full_unstemmed Subcutaneous fast-acting insulin analogues, alone or in combination with long-acting insulin, versus intravenous regular insulin infusion in patients with diabetic ketoacidosis: protocol for an updated systematic review and meta-analysis of randomised trials
title_short Subcutaneous fast-acting insulin analogues, alone or in combination with long-acting insulin, versus intravenous regular insulin infusion in patients with diabetic ketoacidosis: protocol for an updated systematic review and meta-analysis of randomised trials
title_sort subcutaneous fast acting insulin analogues alone or in combination with long acting insulin versus intravenous regular insulin infusion in patients with diabetic ketoacidosis protocol for an updated systematic review and meta analysis of randomised trials
url https://bmjopen.bmj.com/content/13/2/e070131.full
work_keys_str_mv AT bengleonglim subcutaneousfastactinginsulinanaloguesaloneorincombinationwithlongactinginsulinversusintravenousregularinsulininfusioninpatientswithdiabeticketoacidosisprotocolforanupdatedsystematicreviewandmetaanalysisofrandomisedtrials
AT weifenglee subcutaneousfastactinginsulinanaloguesaloneorincombinationwithlongactinginsulinversusintravenousregularinsulininfusioninpatientswithdiabeticketoacidosisprotocolforanupdatedsystematicreviewandmetaanalysisofrandomisedtrials
AT berlinlee subcutaneousfastactinginsulinanaloguesaloneorincombinationwithlongactinginsulinversusintravenousregularinsulininfusioninpatientswithdiabeticketoacidosisprotocolforanupdatedsystematicreviewandmetaanalysisofrandomisedtrials
AT yaneelynettechung subcutaneousfastactinginsulinanaloguesaloneorincombinationwithlongactinginsulinversusintravenousregularinsulininfusioninpatientswithdiabeticketoacidosisprotocolforanupdatedsystematicreviewandmetaanalysisofrandomisedtrials
AT keevooiloo subcutaneousfastactinginsulinanaloguesaloneorincombinationwithlongactinginsulinversusintravenousregularinsulininfusioninpatientswithdiabeticketoacidosisprotocolforanupdatedsystematicreviewandmetaanalysisofrandomisedtrials